Why should heart conditions be monitored with cosentyx?

Why are heart risks flagged with Cosentyx?
Cosentyx (secukinumab) is an IL-17A inhibitor used for psoriasis, psoriatic arthritis, and ankylosing spondylitis. Blocking IL-17 can alter inflammatory pathways that also influence vascular function, so regulators and clinicians watch for changes in cardiac events during treatment.

What heart-related side effects show up in trials?
Pooled data from phase-3 studies reported major adverse cardiovascular events (MACE) at rates of 0.3–0.5 per 100 patient-years, comparable to placebo. A small numerical increase in new-onset hypertension appeared in some extension studies, but absolute numbers stayed low.

How does Cosentyx differ from TNF inhibitors on heart safety?
TNF blockers carry stronger warnings for heart-failure worsening. Cosentyx has not shown the same signal, yet long-term observational data are still limited, so prescribers often prefer echocardiogram or BNP monitoring when patients already have reduced ejection fraction.

When should clinicians check cardiac status before and during Cosentyx?
Baseline lipid panel, blood pressure, and ECG are recommended for patients over 50 or with prior cardiovascular disease. Follow-up labs every 6–12 months help detect early hypertension or lipid shifts that could compound existing risk.

Can patients with existing heart disease still use Cosentyx?
Yes, but rheumatologists and cardiologists usually co-manage these cases. Dose adjustments are not required, yet any new chest pain, shortness of breath, or rapid weight gain should prompt immediate evaluation.

What real-world evidence links Cosentyx to cardiac outcomes?
Claims databases and registries have not identified a consistent rise in myocardial infarction or stroke versus other biologics, but rare post-marketing reports of pericarditis and arrhythmias continue to be tracked by the FDA.

Why are companies challenging this patent?
Secukinumab’s composition-of-matter patent (US 7,807,159) expires in 2028; several biosimilar developers filed IPR petitions in 2023–2024 arguing obviousness over earlier IL-17 disclosures, seeking earlier market entry.

When does exclusivity expire?
Regulatory exclusivity in the US runs until December 2025 for the original plaque-psoriasis indication; additional indications receive separate three-year extensions, pushing full loss of exclusivity to 2028–2029 in most markets.

Can biosimilars enter before patent expiry?
At-risk launches remain unlikely until the 2028 patent cliff, but settlement agreements could allow limited volume entry in 2027 if litigation resolves earlier.

Who makes Cosentyx?
Novartis Pharmaceuticals holds the biologics license; manufacturing occurs at Novartis sites in Switzerland and the US.